{"nctId":"NCT00088530","briefTitle":"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","startDateStruct":{"date":"2004-07"},"conditions":["Lymphoma, Non-Hodgkin"],"count":140,"armGroups":[{"label":"Experimental Arm","type":"EXPERIMENTAL","interventionNames":["Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone"]},{"label":"Comparator Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab"]}],"interventions":[{"name":"pixantrone, cyclophosphamide, vincristine, rituximab, prednisone","otherNames":["BBR2778"]},{"name":"Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed aggressive \\[de novo or transformed\\] NHL according to REAL/WHO classification.\n* At least one objectively measurable lesion as demonstrated by CT, spiral CT, or MRI and plain radiograph of the chest (chest x-ray, for chest lesions only) that can be followed for response as target lesion.\n* Relapse after 2 or more prior regimens of chemotherapy\n* ECOG performance status of 0, 1, or 2\n* Adequate hematologic, renal and hepatic function\n* LVEF ≥50% determined by MUGA scan\n\nExclusion Criteria:\n\n* Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m²\n* Prior allogenic stem cell transplant\n* Histological diagnosis of Burkitt lymphoma, lymphoblastic lymphoma or Mantle cell lymphoma\n* Active CNS lymphoma or HIV-related lymphoma.\n* Any chemotherapy, radiotherapy, or other anticancer treatment (including corticosteroid, 10 or more mg/day of prednisone or equivalent) within the 2 weeks before randomization\n* Pregnant women or nursing mothers","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response (CR) and Complete Response Unconfirmed (CRu)","description":"Proportion of patients with a best response of complete response (CR) or Complete Response unconfirmed (CRu) in the End Of Treatment (EOT) or End Of Study (EOS) analyses by independent assessment in the Intent-to-treat (ITT) population through the End of Treatment (EOT)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"The time between the date of randomization and the date of the initial documentation of progressive/relapsed disease or death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The time between the date of randomization and the date of death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) Lasting at Least 4 Months","description":"The proportion of patients with Complete response or Partial Response with a difference from the first documented objective response to disease progression or death of at least 4 months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":68},"commonTop":["Neutropenia","Anemia","Pyrexia","Thrombocytopenia","Asthenia"]}}}